11/28/2011 10:51:14 AM
BOSTON--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, reported today on a presentation of Bendavia study findings by cardiologist Dr. Robert Kloner, who presented data from three independent labs during the American Heart Association’s (AHA) annual meeting. Bendavia™ is a novel compound that targets the mitochondrion to treat mitochondrial dysfunction including ischemia reperfusion and microvascular injuries. AHA is a U.S. nonprofit organization that focuses on cardiac care worldwide with a goal of reducing morbidity and mortality caused by cardiovascular diseases, the leading cause of death worldwide. The 2011 AHA annual meeting was held November 12 through 16 in Orlando, Florida, and centered on state of the art scientific advances for cardiovascular medicine and biology.
comments powered by